<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05795647</url>
  </required_header>
  <id_info>
    <org_study_id>87RI21_0052 (PENTO)</org_study_id>
    <nct_id>NCT05795647</nct_id>
  </id_info>
  <brief_title>The PENTO Protocol in Medication-related Osteonecrosis of the Jaw</brief_title>
  <acronym>PENTO</acronym>
  <official_title>The PENTO Protocol in Medication-related Osteonecrosis of the Jaw</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Limoges</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Limoges</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Medication-related osteonecrosis of the jaw (MRONJ) occurs after taking bisphosphonates or&#xD;
      targeted therapies. It leads to a significant decrease in quality of life with pain, eating&#xD;
      and chewing disorders, and malnutrition. Current treatments are only partially effective.&#xD;
      PENTO (pentoxifylline and tocopherol) has been shown to be effective in maxillary&#xD;
      osteoradionecrosis. The objective of this study is to evaluate the proportion of bone&#xD;
      recovery in patients receiving PENTO in MRONJ at 12 months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      MRONJ is defined as intraoral bone exposure persisting for more than 8 weeks after taking an&#xD;
      anti-resorptive agent (per os or IV bisphosphonates, targeted therapies) and without history&#xD;
      of maxilla radiotherapy or metastasis. It leads to a significant decrease in quality of life&#xD;
      with significant pain at rest and during mastication, and compromised nutrition, sometimes&#xD;
      resulting in severe undernutrition in patients already weakened by a history of cancer.&#xD;
      Current treatments (prolonged antibiotic therapy, repeated bone curettage) have shown partial&#xD;
      effectiveness. PENTO (combination of pentoxifylline, a vasodilator, and tocopherol, vitamin&#xD;
      E) has been shown to significantly reduce intraoral exposed bone surface area and pain in&#xD;
      maxilla osteoradionecrosis. All studies conducted so far on PENTO in MRONJ are retrospective&#xD;
      or involve small samples. Therefore, our idea is to perform a well-conducted prospective&#xD;
      phase IIa study to prove the efficacy of PENTO, with a larger sample size and identical&#xD;
      follow-up periods. The investigators will study patients with AAOMS stage 2 MRONJ (exposed&#xD;
      bone in symptomatic patients, without pathologic fracture).&#xD;
&#xD;
      Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with&#xD;
      tocopherol 500 mg morning and evening. Antibiotic therapy with Augmentin (or clindamycin)&#xD;
      will be added for the first month and then punctually if signs of local infection appear.&#xD;
&#xD;
      The primary and secondary endpoints will be assessed at inclusion and at 1, 3, 6 and 12&#xD;
      months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 1, 2023</start_date>
  <completion_date type="Anticipated">February 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">February 1, 2025</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Exposure bone area (EBA)</measure>
    <time_frame>Month 12</time_frame>
    <description>exposure bone area (EBA) less than 5 mm at 12 months. It will be expressed as the percentage of patients who achieved healing (EBA &lt; 5 mm) at 12 months.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>SOMA score</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the evolution of the modified SOMA score (pain, chewing, bone exposure size, trismus, radiological appearance)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters evolution (albuminemia)</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the nutritional parameters evolution albuminemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters evolution (pre-albuminemia)</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the nutritional parameters evolution pre-albuminemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters evolution (weight)</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the nutritional parameters evolution weight</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Nutritional parameters evolution (BMI)</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the nutritional parameters evolution BMI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Exposure bone area (EBA)</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>describe the evolution of the exposure bone area (EBA)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability])</measure>
    <time_frame>Month 1, Month 3, Month 6, Month 12</time_frame>
    <description>description of adverse events</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Medication-related Osteonecrosis of the Jaw (MRONJ)</condition>
  <arm_group>
    <arm_group_label>Pentoxifylline</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pentoxifylline+Tocopherol</intervention_name>
    <description>Treatment will consist of pentoxifylline LP 400 mg morning and evening, combined with tocopherol 500 mg morning and evening</description>
    <arm_group_label>Pentoxifylline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age greater than or equal to 18 years&#xD;
&#xD;
          -  Current or past treatment with bisphosphonates (oral or IV) and/or targeted therapies&#xD;
             (denosumab, bevacizumab)&#xD;
&#xD;
          -  Signs and symptoms for more than 8S with confirmation that the signs and symptoms are&#xD;
             not of dental origin&#xD;
&#xD;
          -  AAOMS Stage 2 MRONJ&#xD;
&#xD;
          -  For patients of childbearing age, effective contraception is required&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of head or neck radiotherapy or maxilla metastases&#xD;
&#xD;
          -  Patients who have received treatment in the past (PENTO or PENTOCLO protocol)&#xD;
&#xD;
          -  Patients who have undergone surgery for their MRONJ within the last 3 months&#xD;
&#xD;
          -  Pregnant or wishing to be pregnant, breastfeeding&#xD;
&#xD;
          -  Patient under palliative care&#xD;
&#xD;
          -  Patient with hypersensitivity to pentoxifylline or tocopherol or to an excipient&#xD;
&#xD;
          -  History of hypersensitivity reaction to penicillins, cephalosporins, or other&#xD;
             beta-lactams (or clindamycin or lincomycin if applicable) or excipient of&#xD;
             amoxicillin-a. clavulanic or clindamycin&#xD;
&#xD;
          -  History of jaundice/hepatic injury related to amoxicillin/clavulanic acid&#xD;
&#xD;
          -  Patient taking oral anticoagulants, or with a history of major bleeding or bleeding&#xD;
             disorders&#xD;
&#xD;
          -  Patient taking platelet aggregation inhibitor, theophylline or aminophylline&#xD;
&#xD;
          -  Patient taking methotrexate, probenecid, mycophenolate mofetil, myorelaxant drugs,&#xD;
             macrolide or streptogramin antibiotics&#xD;
&#xD;
          -  Patients with a history of hepatic failure, renal failure (Cl &lt; 30 mL/min),&#xD;
             hypotension (SBP (systolic blood pressure) &lt; 90 mmHg)&#xD;
&#xD;
          -  Patient with hypotension (SBP &lt; 90 mmHg)&#xD;
&#xD;
          -  Refusal to participate in the study&#xD;
&#xD;
          -  Patient participating in other interventional research that may interfere with the&#xD;
             conduct of this research&#xD;
&#xD;
          -  Patient unable to understand the protocol&#xD;
&#xD;
          -  Patient under curatorship or guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julie USSEGLIO, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital, Limoges</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Julie USSEGLIO, Dr</last_name>
    <phone>+33 (0) 555 056 120</phone>
    <email>julie.usseglio@chu-limoges.fr</email>
  </overall_contact>
  <verification_date>March 2023</verification_date>
  <study_first_submitted>December 14, 2022</study_first_submitted>
  <study_first_submitted_qc>March 20, 2023</study_first_submitted_qc>
  <study_first_posted type="Actual">April 3, 2023</study_first_posted>
  <last_update_submitted>March 20, 2023</last_update_submitted>
  <last_update_submitted_qc>March 20, 2023</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2023</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>MRONJ</keyword>
  <keyword>pentoxifylline</keyword>
  <keyword>tocoph√©rol</keyword>
  <keyword>bone exposure</keyword>
  <keyword>renutrition</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteonecrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>alpha-Tocopherol</mesh_term>
    <mesh_term>Pentoxifylline</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

